#United States #New York #SEC Lawsuit #Skye Bioscience #nimacimab

Legal Action Against Skye Bioscience, Inc.

On December 1, 2025, The Gross Law Firm issued a critical announcement targeting shareholders of Skye Bioscience, Inc. (NASDAQ: SKYE), alerting them to a significant legal action based on alleged violations of securities laws. The firm encourages those who purchased shares of Skye during the designated class period to reach out regarding potential lead plaintiff roles.

Context of the Suit

The lawsuit asserts that, during the specified period (November 4, 2024, to October 3, 2025), Skye Bioscience made several materially false and misleading statements about its lead product candidate, nimacimab. According to the complaint, the company overstated the effectiveness and market potential of nimacimab, misleading investors and contributing to inflated stock prices.

The specifics of the allegations include:
1. Misrepresentation of Effectiveness: The firm's executives allegedly conveyed that nimacimab was more effective than it truly was, which led investors to make decisions based on inaccurate data.
2. Overstated Prospects: The lawsuit contends that the clinical, regulatory, and commercial prospects of nimacimab were significantly overstated.
3. Ongoing Misleading Statements: As a result of these issues, the public statements from the company pertaining to nimacimab's performance were deemed materially false and misleading throughout the period in question.

Next Steps for Shareholders

Shareholders are advised to act promptly as the deadline for registering as a lead plaintiff is set for January 16, 2026. To register, interested parties can visit the Gross Law Firm’s dedicated link provided in their announcement. This registration will also enable shareholders to use portfolio monitoring software, ensuring they remain updated about the progress of the case.

The Gross Law Firm has established a reputation as a leading class action litigation firm aimed at safeguarding the rights of investors who have faced losses due to deceptive and fraudulent business practices. They are committed to holding corporations accountable for significantly harming investor interests through misleading statements or omissions.

Why Should Investors Be Concerned?

The implications of such legal battles are far-reaching. Investors may incur substantial financial losses if the accusations hold ground and if the company's stock experiences a retroactive decline due to revelations from the lawsuit. Furthermore, the case highlights an essential aspect of investor diligence - the need to stay informed about ongoing and emerging risks associated with their holdings.

Skye Bioscience’s reliance on nimacimab places the company at a crucial juncture; if the allegations against them hold true, the firm's leadership might face severe repercussions. Investors must be aware that they can partake in this legal action without the necessity of appointing themselves as lead plaintiffs.

For those who have invested in Skye Bioscience, Inc., this situation serves as a reminder of the volatility inherent in biotech investments, particularly those related to product pipelines and regulatory reviews.

In conclusion, early action is vital for shareholders of Skye Bioscience, as the outcome of this litigation could significantly impact their investment returns. Interested shareholders should head to the Gross Law Firm's website to initiate their registration process before the legal registration deadline.

For more information, stakeholders are encouraged to contact The Gross Law Firm via email at [email protected] or via phone at (646) 453-8903.